Nilufar Mossaheb

Dr. Nilufar Mossaheb

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Biological Psychiatry
Verified
Journal Article
Closed access
RLRupert Lanzenberger
Rupert Lanzenberger
Markus MitterhauserMarkus Mitterhauser
Markus Mitterhauser
CSChristoph Spindelegger
Christoph Spindelegger
Wolfgang WadsakWolfgang Wadsak
Wolfgang Wadsak
NKNikolas Klein
Nikolas Klein
JTJohannes Tauscher
Johannes Tauscher

1 January 2017 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
PMPatrick D. McGorry
Patrick D. McGorry
BNBarnaby Nelson
Barnaby Nelson
CMConnie Markulev
Connie Markulev
HYHok Pan Yuen
Hok Pan Yuen
MSMiriam R. Schäfer
Miriam R. Schäfer
GAG. Paul Amminger
G. Paul Amminger
Importance A promising treatment to prevent onset and improve outcomes in patients at ultrahigh risk for psychosis is dietary supplementation with long-chain ω-3 polyunsaturated fatty acids (PUFAs). Objective To determine whether treatment with ω-3 PUFAs in combination with a high-quality psychosocial intervention (cognitive behavioral case management [CBCM]) is more effective than placebo plus CBCM. Design, Setting, and Participants NEURAPRO, a double-blind, placebo-controlled, randomized clinical trial, was conducted from March 1, 2010, to September 30, 2014, in 10 specialized early psychosis treatment services in Australia, Asia, and Europe. The primary analysis used the intention-to-treat approach. Interventions A daily dose of 1.4 g of ω-3 PUFAs or placebo (paraffin oil), plus 20 or fewer sessions of CBCM over the 6-month study period. Main Outcomes and Measures The primary outcome was transition to psychosis status at 6 months. The secondary outcomes were general levels of psychopathology and functioning, as assessed by the Brief Psychiatric Rating Scale (BPRS) (range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Åsberg Depression Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range, 0-44), Social and Occupational Functioning Assessment Scale (SOFAS) (range, 0-100), and the Global Functioning: Social and Role scale (range, 0-10). For SOFAS and Global Functioning: Social and Role scale, higher scores were better; for other measures, lower scores were better. Results In this study of 304 adults at ultrahigh risk for psychotic disorders, 153 (50.3%) received ω-3 PUFAs and 151 (49.7%) received placebo. In all, 139 (45.7%) were male; mean (SD) age was 19.1 (4.6) years. The Kaplan-Meier–estimated 6-month transition rates were 5.1% (95% CI, 1.3%-8.7%) in the control group and 6.7% (95% CI, 2.3%-10.8%) in the ω-3 PUFA group. At 12 months, the rates were 11.2% (95% CI, 5.5%-16.7%) in the control group and 11.5% (95% CI, 5.8%-16.9%) in the ω-3 PUFA group. No significant difference was observed between the transition rates of both groups (hazard ratio, 1.1; 95% CI, 0.55-2.23;P = .76, stratified log-rank test). Conclusions and Relevance This trial clearly failed to replicate the findings of the original single-center trial. The most likely explanation is that ω-3 PUFAs lack efficacy under these conditions. However, the lower-than-expected transition rate may have prevented a test of the main hypothesis. Given the substantial symptomatic and functional improvement in both groups, the other treatments received (ie, CBCM and antidepressants) likely produced a ceiling effect beyond which ω-3 PUFAs, even if effective, could not be shown to confer additional benefits. Nevertheless, the main conclusion is that ω-3 PUFAs are not effective under conditions where good quality, evidence-based psychosocial treatment is available. Trial Registration anzctr.org.au Identifier:12608000475347

21 March 2011 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
GAG. Paul Amminger
G. Paul Amminger
MSMiriam R. Schäfer
Miriam R. Schäfer
KPKonstantinos Papageorgiou
Konstantinos Papageorgiou
CKClaudia M. Klier
Claudia M. Klier
MSMonika Schlögelhofer
Monika Schlögelhofer
PMPatrick D. McGorry
Patrick D. McGorry
Problems in the perception of emotional material, in particular deficits in the recognition of negative stimuli, have been demonstrated in schizophrenia including in first-episode samples. However, it is largely unknown if emotion recognition impairment is present in people with subthreshold psychotic symptoms. Here, we examined the capacity to recognize facially expressed emotion and affective prosody in 79 individuals at ultra high-risk for psychosis, 30 clinically stable individuals with first-episode schizophrenia assessed as outpatients during the early recovery phase of illness, and 30 unaffected healthy control subjects. We compared (1) scores for a combined fear-sadness aggregate index across face and voice modalities, (2) summary scores of specific emotions across modalities, and (3) scores for specific emotions for each sensory modality. Findings supported deficits in recognition of fear and sadness across both modalities for the clinical groups (the ultra high-risk and first-episode group) as compared with the healthy controls. Furthermore, planned contrasts indicated that compared with the healthy control subjects, both clinical groups had a significant deficit for fear and sadness recognition in faces and for anger recognition in voices. Specific impairments in emotion recognition may be apparent in people at clinical high-risk for schizophrenia before the full expression of psychotic illness. The results suggest a trait deficit and an involvement of the amygdala in the pathology of ultra high-risk states.

1 May 2011 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
NKNestor D. Kapusta
Nestor D. Kapusta
NMNilufar Mossaheb
Nilufar Mossaheb
EEElmar Etzersdorfer
Elmar Etzersdorfer
GHGerald Hlavin
Gerald Hlavin
KTKenneth Thau
Kenneth Thau
KLKatharina Leithner-Dziubas
Katharina Leithner-Dziubas
Background: There is some evidence that natural levels of lithium in drinking water may have a protective effect on suicide mortality.Aims: To evaluate the association between local lithium levels in drinking water and suicide mortality at district level in Austria.Method: A nationwide sample of 6460 lithium measurements was examined for association with suicide rates per 100 000 population and suicide standardised mortality ratios across all 99 Austrian districts. Multivariate regression models were adjusted for well-known socioeconomic factors known to influence suicide mortality in Austria (population density, per capita income, proportion of Roman Catholics, as well as the availability of mental health service providers). Sensitivity analyses and weighted least squares regression were used to challenge the robustness of the results.Results: The overall suicide rate (R2= 0.15, β =–0.39,t=–4.14,P= 0.000073) as well as the suicide mortality ratio (R2= 0.17, β =–0.41,t=–4.38,P= 0.000030) were inversely associated with lithium levels in drinking water and remained significant after sensitivity analyses and adjustment for socioeconomic factors.Conclusions: In replicating and extending previous results, this study provides strong evidence that geographic regions with higher natural lithium concentrations in drinking water are associated with lower suicide mortality rates.

1 November 2012 in Schizophrenia Research
Verified
Journal Article
Closed access
NMNilufar Mossaheb
Nilufar Mossaheb
JBJana Becker
Jana Becker
MSMiriam R. Schaefer
Miriam R. Schaefer
CKClaudia M. Klier
Claudia M. Klier
MSMonika Schloegelhofer
Monika Schloegelhofer
GAG. Paul Amminger
G. Paul Amminger

22 August 2007 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
JSJulia Sacher
Julia Sacher
NMNilufar Mossaheb
Nilufar Mossaheb
CSChristoph Spindelegger
Christoph Spindelegger
NKNikolas Klein
Nikolas Klein
TGThomas Geiss-Granadia
Thomas Geiss-Granadia
SKSiegfried Kasper
Siegfried Kasper
Atypical antipsychotics have been linked to a higher risk for glucose intolerance, and consequentially the development of type 2 diabetes mellitus (DM2). We have therefore set out to investigate the acute effects of oral administration of olanzapine and ziprasidone on whole body insulin sensitivity in healthy subjects. Using the standardized hyperinsulinemic euglycemic clamp technique we compared whole body insulin sensitivity of 29 healthy male volunteers after oral intake of either olanzapine 10 mg/day (n=14) or ziprasidone 80 mg/day (n=15) for 10 days. A significant decrease (p<0.001) in whole body insulin sensitivity from 5.7 ml/h/kg (=mean, SM=0.4 ml/h/kg) at baseline to 4.7 ml/h/kg (=mean, SM=0.3 ml/h/kg) after oral intake of olanzapine (10 mg/day) for 10 days was observed. The ziprasidone (80 mg/day) group did not show any significant difference (5.2±0.3 ml/h/kg baseline vs 5.1±0.3 ml/h/kg) after 10 days of oral intake. Our main finding demonstrates that oral administration of olanzapine but not ziprasidone leads to a decrease in whole body insulin sensitivity in response to a hyperinsulinemic euglycemic challenge. Our finding is suggestive that not all atypical antipsychotics cause acute direct effects on glucose disposal and that accurate determination of side effect profile should be performed when choosing an atypical antipsychotic.